Current Report Filing (8-k)
May 15 2020 - 6:04AM
Edgar (US Regulatory)
0000885725
false
0000885725
2020-05-13
2020-05-14
0000885725
us-gaap:CommonStockMember
2020-05-13
2020-05-14
0000885725
bsx:SeniorNoteDue2027Member
2020-05-13
2020-05-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 14, 2020
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
|
1-11083
|
|
04-2695240
|
(State or other jurisdiction of incorporation or
organization)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer Identification
No.)
|
300 Boston Scientific Way, Marlborough, Massachusetts
|
|
01752-1234
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
508 683-4000
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share
|
|
BSX
|
|
New York Stock Exchange
|
0.625% Senior Notes due 2027
|
|
BSX27
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM
8.01 Other Events
On
May 14, 2020, Boston Scientific Corporation (the “Company”) announced the pricing of a public offering of $1.7
billion aggregate principal amount of its senior notes under the Company’s shelf registration statement. The public offering
consists of $500.0 million in aggregate principal amount of 1.900% notes due 2025 and $1.2 billion in aggregate principal amount
of 2.650% notes due 2030. The Company expects the offering to close on May 18, 2020, subject to customary closing conditions. The
Company intends to use the net proceeds from this offering to (i) refinance $450.0 million of borrowings under its revolving credit
facility and a portion of its pre-payable bank debt, including $750.0 million under its $1.0 billion term loan credit facility
maturing in February 2021 and $500.0 million under its $1.25 billion term loan credit facility maturing in April 2021 and (ii)
pay related fees, expenses and premiums.
A copy
of the press release is filed with this report as Exhibit 99.1 and incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND
EXHIBITS.
(d) Exhibits
Exhibit No. Description
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 14, 2020
|
BOSTON SCIENTIFIC CORPORATION
|
|
|
|
|
By:
|
/s/ Vance R. Brown
|
|
|
Vance R. Brown
|
|
|
Vice President and Chief Corporate Counsel
|
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Sep 2023 to Sep 2024